Back to results
US 6,284,538 B1Granted
Antisense inhibition of PTEN expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsBrett P. Monia, Lex M. Cowsert, Robert McKay
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeIsis Pharmaceuticals, Inc.
InventorsBrett P. Monia, Lex M. Cowsert, Robert McKay
Estimating the term…
Antisense compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases and conditions associated with expression of PTEN are provided. Such conditions include diabetes and hyperproliferative conditions. Methods for decreasing blood glucose levels, inhibiting PEPCK expression, decreasing blood insulin levels, decreasing insulin resistance, increasing insulin sensitivity, decreasing blood triglyceride levels or decreasing blood cholesterol levels in an animal using the compounds of the invention are also provided. The animal is preferably a human; also preferably the animal is a diabetic animal.
A compound target to a nucleic acid molecule encoding PTEN wherein the compound is an antisense oligonucleotide having a sequence consisting of SEQ ID NOS:
A method of treating an animal having diabetes associated with PTEN expressions comprising administering to said diabetic animal a therapeutically or prophylactically effective amount of an antisense oligonucleotide having a sequence consisting of SEQ ID NO:48 or SEQ ID NO:49 so that expression of PTEN is inhibited and blood glucose levels of said animal are decreased.
A method of inhibiting expression of PEPCK, phosphoenolpyruvate carboxykinase, in cells or tissues from a diabetic animal comprising contacting said cells or tissues from a diabetic animal with an antisense oligonucleotide having a sequence consisting of SEQ ID NO:48 or SEQ ID NO:49 so that both expression of PEPCK and PTEN are inhibited.
A method of decreasing blood insulin levels in a diabetic animal comprising administering to said diabetic animal an antisense oligonucleotide having a sequence consisting of SEQ ID NO:48 or SEQ ID NO:49 wherein expression of PTEN is inhibited and blood insulin levels are decreased.
A method of decreasing insulin resistance in a diabetic animal comprising administering to said diabetic animal an antisense oligonucleotide having a sequence consisting of SEQ ID NO:48 or SEQ ID NO:49 wherein expression of PTEN is inhibited and insulin resistance is decreased.
A method of increasing insulin sensitivity in a diabetic animal comprising administering to said diabetic animal an antisense oligonucleotide having a sequence consisting of SEQ ID NO:48 or SEQ ID NO:49 wherein expression of PTEN is inhibited and insulin sensitivity is increased.
A method of decreasing blood triglyceride levels in a diabetic animal comprising administering to said diabetic animal an antisense oligonucleotide having a sequence consisting of SEQ ID NO:48 or SEQ ID NO:49 wherein expression of PTEN is inhibited and blood triglyceride levels are decreased.
A method of decreasing blood cholesterol levels in a diabetic animal comprising administering to said diabetic animal an antisense oligonucleotide having a sequence consisting of SEQ ID NO:48 or SEQ ID NO:49 wherein expression of PTEN is inhibited and blood cholesterol levels are decreased.
Dependencies are inferred from the claim text.